DIAMOND STUART 4
4 · bioAffinity Technologies, Inc. · Filed Dec 2, 2022
Insider Transaction Report
Form 4
DIAMOND STUART
Director
Transactions
- Purchase
Common Stock, par value $0.007
2022-08-31+4,081→ 4,081 total - Purchase
Warrants (right to buy)
2022-08-31+4,081→ 4,081 totalExercise: $7.35From: 2022-08-31Exp: 2027-08-31→ Common Stock (4,081 underlying) - Purchase
Non-tradeable Warrants (right to buy)
2022-08-31+4,081→ 4,081 totalExercise: $7.66From: 2022-08-31Exp: 2027-08-31→ Common Stock (4,081 underlying)
Footnotes (2)
- [F1]The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").
- [F2]The reported securities are included within 4,081 Units purchased by Mr. Diamond for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.